150 related articles for article (PubMed ID: 37576979)
1. Editorial: Targeting different programmed cell death processes as therapeutic modalities for thyroid cancer.
Rajabi S
Front Endocrinol (Lausanne); 2023; 14():1255259. PubMed ID: 37576979
[No Abstract] [Full Text] [Related]
2. PD-1 Ligand Expression in Epithelial Thyroid Cancers: Potential Clinical Implications.
Ulisse S; Tuccilli C; Sorrenti S; Antonelli A; Fallahi P; D'Armiento E; Catania A; Tartaglia F; Amabile MI; Giacomelli L; Metere A; Cornacchini N; Pironi D; Carbotta G; Vergine M; Monti M; Baldini E
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30897754
[TBL] [Abstract][Full Text] [Related]
3. Carcinogenesis and therapeutic strategies in thyroid cancer.
Liu ZM; Wu TT; van Hasselt CA; Chen GG
Curr Drug Targets; 2010 Jun; 11(6):716-32. PubMed ID: 20298151
[TBL] [Abstract][Full Text] [Related]
4. Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy.
Schürch CM; Roelli MA; Forster S; Wasmer MH; Brühl F; Maire RS; Di Pancrazio S; Ruepp MD; Giger R; Perren A; Schmitt AM; Krebs P; Charles RP; Dettmer MS
Thyroid; 2019 Jul; 29(7):979-992. PubMed ID: 30938231
[No Abstract] [Full Text] [Related]
5. MicroRNA-21 regulates biological behaviors in papillary thyroid carcinoma by targeting programmed cell death 4.
Zhang J; Yang Y; Liu Y; Fan Y; Liu Z; Wang X; Yuan Q; Yin Y; Yu J; Zhu M; Zheng J; Lu X
J Surg Res; 2014 Jun; 189(1):68-74. PubMed ID: 24650454
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Foxp3 in cancer cells induces apoptosis of thyroid cancer cells.
Chu R; Liu SY; Vlantis AC; van Hasselt CA; Ng EK; Fan MD; Ng SK; Chan AB; Du J; Wei W; Liu X; Liu Z; Chen GG
Mol Cell Endocrinol; 2015 Jan; 399():228-34. PubMed ID: 25312920
[TBL] [Abstract][Full Text] [Related]
7. Oncogenes, mitochondrial metabolism, and quality control in differentiated thyroid cancer.
Yi HS; Chang JY; Kim KS; Shong M
Korean J Intern Med; 2017 Sep; 32(5):780-789. PubMed ID: 28823142
[TBL] [Abstract][Full Text] [Related]
8. Signaling Pathways in Thyroid Cancer.
Jin S; Yang YT; Bao W
Vitam Horm; 2018; 106():501-515. PubMed ID: 29407446
[TBL] [Abstract][Full Text] [Related]
9. Targeting COPZ1 non-oncogene addiction counteracts the viability of thyroid tumor cells.
Anania MC; Cetti E; Lecis D; Todoerti K; Gulino A; Mauro G; Di Marco T; Cleris L; Pagliardini S; Manenti G; Belmonte B; Tripodo C; Neri A; Greco A
Cancer Lett; 2017 Dec; 410():201-211. PubMed ID: 28951131
[TBL] [Abstract][Full Text] [Related]
10. Inhibitor of apoptosis protein Livin promotes tumor progression and chemoradioresistance in human anaplastic thyroid cancer.
Kim HK; Kim SA; Jung EK; Lee KH; Lee JK; Kang HC; Joo YE; Lim SC; Yoon TM
Oncol Rep; 2021 Apr; 45(4):. PubMed ID: 33649820
[TBL] [Abstract][Full Text] [Related]
11. PROGRAMMED CELL DEATH-LIGAND 1 OVEREXPRESSION IN THYROID CANCER.
Zhang GQ; Wei WJ; Song HJ; Sun ZK; Shen CT; Zhang XY; Chen XY; Qiu ZL; Luo QY
Endocr Pract; 2019 Mar; 25(3):279-286. PubMed ID: 30913016
[TBL] [Abstract][Full Text] [Related]
12. Predictive relevance of programmed cell death protein 1 and tumor-infiltrating lymphocyte expression in papillary thyroid cancer.
Aghajani MJ; Yang T; McCafferty CE; Graham S; Wu X; Niles N
Surgery; 2018 Jan; 163(1):130-136. PubMed ID: 29128181
[TBL] [Abstract][Full Text] [Related]
13. Thyroid cancer molecular signaling pathways and use of targeted therapy.
Kundra P; Burman KD
Endocrinol Metab Clin North Am; 2007 Sep; 36(3):839-53, viii. PubMed ID: 17673131
[TBL] [Abstract][Full Text] [Related]
14. Programmed Death-Ligand 1 (PD-L1) Is a Potential Biomarker of Disease-Free Survival in Papillary Thyroid Carcinoma: a Systematic Review and Meta-Analysis of PD-L1 Immunoexpression in Follicular Epithelial Derived Thyroid Carcinoma.
Girolami I; Pantanowitz L; Mete O; Brunelli M; Marletta S; Colato C; Trimboli P; Crescenzi A; Bongiovanni M; Barbareschi M; Eccher A
Endocr Pathol; 2020 Sep; 31(3):291-300. PubMed ID: 32468210
[TBL] [Abstract][Full Text] [Related]
15. Molecular elements of apoptosis-regulating pathways in follicular thyroid cells: mining for novel therapeutic targets in the treatment of thyroid carcinoma.
Sarlis NJ; Gourgiotis L
Curr Drug Targets Immune Endocr Metabol Disord; 2004 Sep; 4(3):187-98. PubMed ID: 15379722
[TBL] [Abstract][Full Text] [Related]
16. Ym155 Induces Oxidative Stress-Mediated DNA Damage and Cell Cycle Arrest, and Causes Programmed Cell Death in Anaplastic Thyroid Cancer Cells.
Xu Q; Mackay RP; Xiao AY; Copland JA; Weinberger PM
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669447
[TBL] [Abstract][Full Text] [Related]
17. [Intracellular signaling mechanisms in thyroid cancer].
Mondragón-Terán P; López-Hernández LB; Gutiérrez-Salinas J; Suárez-Cuenca JA; Luna-Ceballos RI; Erazo Valle-Solís A
Cir Cir; 2016; 84(5):434-43. PubMed ID: 27423883
[TBL] [Abstract][Full Text] [Related]
18. Novel targeted therapies and immunotherapy for advanced thyroid cancers.
Naoum GE; Morkos M; Kim B; Arafat W
Mol Cancer; 2018 Feb; 17(1):51. PubMed ID: 29455653
[TBL] [Abstract][Full Text] [Related]
19. Role of NF-kappaB in thyroid cancer.
Pacifico F; Leonardi A
Mol Cell Endocrinol; 2010 May; 321(1):29-35. PubMed ID: 19879919
[TBL] [Abstract][Full Text] [Related]
20. Editorial: New strategies in treatment of differentiated thyroid carcinoma.
Carrillo JF; Suarez C; Sanabria A; Onerci TM; Savant D
Front Endocrinol (Lausanne); 2022; 13():1004734. PubMed ID: 36093118
[No Abstract] [Full Text] [Related]
[Next] [New Search]
